Com­pa­ny found­ed by ex-No­var­tis ex­ecs inks $477M in-li­cense deal

Adi­tum Bio, the biotech fund launched by two for­mer No­var­tis ex­ecs, an­nounced that it formed a new com­pa­ny fo­cused on de­vel­op­ing treat­ments for im­muno­log­i­cal dis­or­ders, in­clud­ing an ear­ly-stage ther­a­py it’s li­cens­ing from Dae­woong Phar­ma­ceu­ti­cal.

Ac­cord­ing to Dae­woong’s cor­re­spond­ing an­nounce­ment Thurs­day night, Vi­tal­li Bio plans to make an up­front pay­ment of $10 mil­lion to the South Ko­re­an drug­mak­er for ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights to au­toim­mune dis­ease drug can­di­date DWP213388, a BTK and ITK-tar­get­ing can­di­date that re­ceived IND clear­ance from the FDA last Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER